SEC Company Response from Clinuvel Pharmaceuticals (CUVL) — Jul 6, 2026

Clinuvel Pharmaceuticals Ltd
Date: July 6, 2026 · CIK: 0001290877 · Accession: 0001493152-26-032101

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-43353

Date

July 6, 2026

Author

Pharmaceuticals Limited

Form

CORRESP

Company

Clinuvel Pharmaceuticals Ltd

Letter

Clinuvel Pharmaceuticals Limited

July 6, 2026

Via EDGAR

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

F Street, NE

Washington, D.C., 20549

Attention:

Vanessa Robertson

Bonnie Baynes Joe McCann Lauren Sprague Hamill

Re: Clinuvel Pharmaceuticals Limited

Registration Statement on Form 20-F

File No. 001-43353

Ladies and Gentlemen:

Pursuant to Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended, Clinuvel Pharmaceuticals Limited (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement on Form 20-F (File No. 001-43353) to become effective at 4:00 p.m. Eastern time on July 8, 2024, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request by telephone call to the staff of the Commission.

Very
truly yours,
Clinuvel
Pharmaceuticals Limited

Show Raw Text

CORRESP
 1
 filename1.htm

 Clinuvel
Pharmaceuticals Limited

 July
6, 2026

 Via
EDGAR

 Division
of Corporation Finance

 Office
of Life Sciences

 U.S.
Securities and Exchange Commission

 100
F Street, NE

 Washington,
D.C., 20549

 Attention:

 Vanessa
 Robertson

 Bonnie
 Baynes
 Joe
 McCann
 Lauren
 Sprague Hamill

 Re:
 Clinuvel
 Pharmaceuticals Limited

 Registration
 Statement on Form 20-F

 File
 No. 001-43353

 Ladies
and Gentlemen:

 Pursuant
to Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended, Clinuvel Pharmaceuticals Limited (the "Registrant")
hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to cause the
Registration Statement on Form 20-F (File No. 001-43353) to become effective at 4:00 p.m. Eastern time on July 8, 2024, or as soon thereafter
as practicable, or at such later time as the Registrant or its counsel may orally request by telephone call to the staff of the Commission.

 Very
 truly yours,

 Clinuvel
 Pharmaceuticals Limited

 By:
 /s/
 Philippe Wolgen

 Name:

 Philippe
 Wolgen

 Title:

 Managing
 Director and Chief Executive Officer

SecProbe.io